



Technical Advisory Group Recommendations on Meningococcal Conjugate Vaccine Requirement for Schools

Washington State Board of Health
January 13, 2016

Michele Roberts, MPH, MCHES, Director, Office of Immunization and Child Profile

PUBLIC HEALTH
ALWAYS WORKING FOR A SAFER AND
HEALTHIER COMMUNITY



Framework to Consider

- An individual's decision could place others' health in jeopardy
- The state's economic interests could be threatened by the costs of care for vaccine preventable illness, related disability, or death, and by the cost of managing vaccine preventable disease outbreaks
- The state's duty to educate children could be compromised


Criteria for Reviewing Antigens for Potential Inclusion in School Immunization Requirements

- I. Criteria on the effectiveness of the vaccine
- II. Disease Burden Criteria
- III. Implementation Criteria

I. Criteria on the effectiveness of the vaccine

1. Recommended by ACIP

MCV4 ACIP Recommendations



TAG Recommendation: Recommended by ACIP

Response	Yes	No	Unsure
Votes	13	0	0

I. Criteria on the effectiveness of the vaccine

2. Vaccine efficacy

Vaccine Effectiveness

- 80-85% vaccine effectiveness (VE)
- Waning effectiveness; not protected 5 years after vaccination
- 2010 ACIP updated recommendations to add booster dose at 16 years of age

Source: CDC. Prevention and control of meningococcal disease: Recommendations of the ACIP. MMWR 2013; 62(No. RR02): 1-22.

TAG Recommendation: Vaccine Efficacy

Response	Yes	No	Unsure
Votes	9	0	4

I. Criteria on the effectiveness of the vaccine

3. Cost effectiveness

Cost Effectiveness

- \$633,000 per meningococcal case prevented
- \$121,000 per life-year saved

Source: CDC. Prevention and control of meningococcal disease: Recommendations of the ACIP. MMWR 2013; 62(No. RR02): 1-22.

TAG Recommendation: Cost Effectiveness

Response	Yes	No	Unsure
Votes	7	4	2

I. Criteria on the effectiveness of the vaccine

4. Safety and Side Effects

Most Frequently Reported Adverse Events

- Fever
- Headache
- Injection-site reactions
- Dizziness/syncope

TAG Recommendation: Safety and Side Effects

Response	Yes	No	Unsure
Votes	13	0	0

II. Disease Burden Criteria

1. Disease prevention

Disease Prevention

- Decline in incidence annually since peak in late 1990s
- Since 2005, declines have occurred among all age groups and in all vaccine-containing serogroups
- Outbreaks have accounted for 2-3% of all cases in the US

Source: CDC. Prevention and control of meningococcal disease: Recommendations of the ACIP. MMWR 2013; 62(No. RR02): 1-22.

TAG Recommendation: Disease Prevention

Response	Yes	No	Unsure
Votes	8	2	3

II. Disease burden criteria

2. Reduction in transmission

Reduction in Transmission

- Spread from person-to-person by sharing secretions during close or lengthy contact.
- The vaccine prevents invasive disease in an individual but we don't have good data on whether the vaccine reduces the carriage of disease among people in any given group, such as a classroom.
- People can "carry" the bacteria without getting sick.
- Carriers do not have any symptoms of meningococcal disease.
- Most cases (97 or 98 out of 100) appear to be random and aren't linked to other cases.


TAG Recommendation: Reduction in Transmission

Response	Yes	No	Unsure
Votes	5	6	2

III. Implementation criteria

- 1. The vaccine is acceptable to the medical community and the public**

Meningococcal and Tdap Vaccine Coverage Rates NIS, US and WA State 2009-2014



TAG Recommendation: The vaccine is acceptable to the medical community and the public

Response	Yes	No	Unsure
Votes	13	0	0

III. Implementation criteria

2. The administrative burdens of delivery and tracking of vaccine are reasonable

Vaccine Doses Ordered in WA, 2010-2014

Year	MCV4	Tdap
2010	95,220	109,550
2011	120,780	118,630
2012	124,515	141,450
2013	120,275	95,060
2014	124,750	94,170

MCV4 vaccines have been available through the VFC Program since 2006

**TAG Recommendation:
The administrative burdens of delivery and tracking of vaccine are reasonable**

Response	Yes	No	Unsure
Votes	7	3	3

III. Implementation criteria

3. The burden of compliance for the vaccine reasonable for the parent/caregiver

Washington State

- Washington is a universal state
 - ✓ State purchases vaccines for all kids
 - ✓ Combination of state and federal funding
- Cost: about \$85/dose through CDC contract
 - ✓ Administration fee: depends by payer and provider contracts (between <\$6-\$35). Covered by insurance. Office visit fee possible.
- Other costs (parents, provider, school)

TAG Recommendation: The burden of compliance for the vaccine reasonable for the parent/caregiver

Response	Yes	No	Unsure
Votes	10	1	2

TAG Recommendation

“I recommend that the Board add the meningococcal vaccine to the rule.”

Response	Yes	No	Unsure
Votes	2	<u>8</u>	3

Questions?

Michele Roberts, MPH, MCHES
Director, Office of Immunization and Child Profile
Michele.Roberts@doh.wa.gov
(360) 236-3110